Sat. Feb 8th, 2025

Update: UCB’s Bepranemab Shows Promise In Alzheimer’s

ByLisa Luckas

10/22/2024
brown brain decor in selective-focus photography
  • UCB’s Phase 2a study of bepranemab, an anti-tau antibody for Alzheimer’s, will be presented at CTAD 2024. The study shows promise in delaying disease progression.
  • UCB regained global rights from Roche/Genentech.

Tue Oct 22 06:00:50 -0000 2024 UTC– UCB announced results of Phase 2a study on bepranemab, an anti-tau antibody for Alzheimer’s, accepted for CTAD 2024 presentation.

The Clinical Trials on Alzheimer’s Disease conference (CTAD) will be held in Madrid (Spain) on October 29 – November 1, 2024.

The study shows potential to delay disease progression. Symposium on October 31, 2024, will discuss clinical and imaging data. UCB regains global rights to bepranemab.

Blackrock owns close to 5% of UCB, it recently revealed.

Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:

About Lisa

Subscribe to Lisa’s Newsletter today!

Keep Up: Nobot.News Launches Breaking Newsletter

Read more Business News as it happens!

Business

ByLisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *